Recombinant Human Udp-Glucuronosyltransferase 1A4 (UGT1A4) Protein (His)

Name: Recombinant Human Udp-Glucuronosyltransferase 1A4 (UGT1A4) Protein (His)
Brand: Beta LifeScience
SKU: BLC-08190P
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Product Overview

Description	Recombinant Human Udp-Glucuronosyltransferase 1A4 (UGT1A4) Protein (His) is produced by our E.coli expression system. This is a full length protein.
Purity	Greater than 90% as determined by SDS-PAGE.
Uniprotkb	P22310
Target Symbol	UGT1A4
Synonyms	Bilirubin UDP glucuronosyltransferase isozyme 2; Bilirubin-specific UDPGT isozyme 2; HUG-BR2; UD14_HUMAN; UDP glucuronosyltransferase 1 family polypeptide A4; UDP glycosyltransferase 1 family polypeptide A4; UDP-glucuronosyltransferase 1-4; UDP-glucuronosyltransferase 1-D; UDP-glucuronosyltransferase 1A4; UDPGT 1-4; UDPGT; UGT-1D; UGT1*4; UGT1-04; UGT1.4; UGT1A4; UGT1D
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-6His
Target Protein Sequence	GKVLVVPTDGSPWLSMREALRELHARGHQAVVLTPEVNMHIKEEKFFTLTAYAVPWTQKEFDRVTLGYTQGFFETEHLLKRYSRSMAIMNNVSLALHRCCVELLHNEALIRHLNATSFDVVLTDPVNLCGAVLAKYLSIPAVFFWRYIPCDLDFKGTQCPNPSSYIPKLLTTNSDHMTFLQRVKNMLYPLALSYICHTFSAPYASLASELFQREVSVVDLVSYASVWLFRGDFVMDYPRPIMPNMVFIGGINCANGKPLSQEFEAYINASGEHGIVVFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQNDLLGHPMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVLEMTSEDLENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAHDLTWYQYHSLDVIGFLLAVVLTVAFITFKCCAYGYRKCLGKKGRVKKAHKSKTH
Expression Range	29-534aa
Protein Length	Full Length of Mature Protein
Mol. Weight	61.0kDa
Research Area	Signal Transduction
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile. Essential for the elimination and detoxification of drugs, xenobiotics and endogenous compounds. Involved in the glucuronidation of calcidiol, which is the major circulating form of vitamin D3 essential for the regulation of calcium and phosphate homeostasis. Also glucuronidates the biologically active form of vitamin D3, calcitriol, probably leading to its biliary transport and intestinal reabsorption.; Lacks UDP-glucuronosyltransferase (UGT) activity but acts as a negative regulator of isoform 1.
Subcellular Location	Endoplasmic reticulum membrane; Single-pass membrane protein.
Protein Families	UDP-glycosyltransferase family
Database References	HGNC: 12536 OMIM: 143500 KEGG: hsa:54657 STRING: 9606.ENSP00000362508 UniGene: Hs.554822
Associated Diseases	Gilbert syndrome (GILBS); Crigler-Najjar syndrome 1 (CN1); Crigler-Najjar syndrome 2 (CN2)
Tissue Specificity	[Isoform 1]: Expressed in liver. Expressed in kidney, colon and small intestine. Not expressed in esophagus. Not expressed in skin.; [Isoform 2]: Expressed in liver, kidney, colon, esophagus and small intestine.

Gene Functions References

Plant steroids competitively inhibited the UGT1A4-catalyzed trifluoperazine glucuronidation reaction suggesting potential for herb-drug interactions to occur. PMID: 27208893
Our findings highlight the influence of UGTT1A4 haplotypes on tamoxifen disposition in Asian breast cancer patients, while genetic variants in UGT2B7 and UGT2B15 appear to be of minor importance. PMID: 27098059
This study aimed to analyze the relationship of UGT2B7 and UGT1A4 polymorphisms with metabolism of valproic acid (VPA) and lamotrigine (LTG) in epileptic children. UGT1A4 L48V polymorphism was not related with the serum concentration of LTG (F=5.328, P=0.006). L48V polymorphism also showed effects on efficacy of LTG (chi2=17.397, P=0.001). PMID: 27795544
No association between non-bullous skin reactions from lamotrigine and heterozygosity of UGT1A4 genetic variants *2(P24T) or *3(L48V) in Norwegian patients. PMID: 28068583
The frequencies of two common UGT1A4 variants, *2 (P24T) and *3 (L48V), and their potential effects on serum concentrations of LTG. PMID: 25492569
Influence of valproic acid concentration and polymorphism of UGT1A4*3, UGT2B7 -161C > T and UGT2B7*2 on serum concentration of lamotrigine in Chinese epileptic children PMID: 26303110
This descriptive study examines correlations between concentrations of tamoxifen's glucuronide metabolites and genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 in 132 patients with estrogen receptor-positive breast cancer under treatment with tamoxifen PMID: 26176234
The association between the UGT1A4 promoter and coding region SNPs and the glucuronidation rates of Tam. PMID: 24917585
Correlation of the UGT1A4 gene polymorphism with serum concentration and therapeutic efficacy of lamotrigine in Han Chinese of Northern China PMID: 24820767
Human UGT1A4 and UGT1A3 conjugate 25-hydroxyvitamin D3. PMID: 24641623
the substrate specificity of UGT2B10, highlighting its preference for tertiary amines with higher affinities and clearance values than those of UGT1A4 and UGT1A3. PMID: 23611809
Present results could be helpful to improve the use of UGT1A4 drug substrates in order to adjust them to the ethnic background of a given population, specifically for Hispanics. PMID: 23277392
study to determine the allelic frequency of two most common defective alleles: UGT1A4*2 and UGT1A4*3 in a Jordanian population PMID: 22367373
Polymorphic glucuronidation of olanzapine by uridine diphosphate glucuronosyltransferase 1A4 (UGT1A4) was investigated retrospectively in patient samples PMID: 22713701
Study identified a large number of genetic variations, including 13 intronic, 39 promoter, as well as 14 exonic polymorphisms, with 10 that lead to amino-acid changes. PMID: 19890225
UGT1A4(P24T) and UGT1A4(L48V) on LTG glucuronidation may lead to interindividual variations in lamotrigine metabolism in vivo PMID: 22047493
The frequencies of the heterozygous alleles for L48V or P24T polymorphisms were 22.4% and 3.8%, respectively. L48V polymorphism was found to decrease the serum lamotrigine concentration in Turkish epilepsy patients on monotherapy or polytherapy. PMID: 21601426
kinetic studies with recombinant UGT1A4 using various substrates: dihydrotestosterone, trans-androsterone, tamoxifen, lamotrigine -- evidence for multiple substrate binding sites PMID: 20007295
Two polymorphisms of the hepatic UGT1A4 protein show a differential metabolic activity toward mutagenic amines and endogenous steroids, altering hepatic metabolism and detoxification. PMID: 15057901
hepatic clearance of trifluoperazine by UGT1A4 did not reach maximum levels until 18.9 years of age PMID: 17556526
AhR-mediated regulation of the human UGT1A4 gene by two xenobiotic response elements and a modulation by single nucleotide polymorphisms is demonstrated PMID: 18433817

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.